NCT04572802

Brief Summary

To explore the severity of diabetic patients with coronary heart disease and the change of serum orphanin FQ content in different diabetic courses

Trial Health

87
On Track

Trial Health Score

Automated assessment based on enrollment pace, timeline, and geographic reach

Enrollment
100

participants targeted

Target at P50-P75 for all trials

Timeline
Completed

Started Oct 2020

Shorter than P25 for all trials

Geographic Reach
1 country

1 active site

Status
completed

Health score is calculated from publicly available data and should be used for screening purposes only.

Trial Relationships

Click on a node to explore related trials.

Study Timeline

Key milestones and dates

First Submitted

Initial submission to the registry

September 29, 2020

Completed
2 days until next milestone

First Posted

Study publicly available on registry

October 1, 2020

Completed
9 days until next milestone

Study Start

First participant enrolled

October 10, 2020

Completed
8 months until next milestone

Primary Completion

Last participant's last visit for primary outcome

June 1, 2021

Completed
4 months until next milestone

Study Completion

Last participant's last visit for all outcomes

September 30, 2021

Completed
Last Updated

April 20, 2022

Status Verified

April 1, 2022

Enrollment Period

8 months

First QC Date

September 29, 2020

Last Update Submit

April 18, 2022

Conditions

Keywords

Type 2 diabetes

Outcome Measures

Primary Outcomes (1)

  • Gensini score

    Gensini score was used to evaluate the severity of coronary artery occlusion, and then compared with the population of type 2 diabetes complicated with coronary heart disease

    1 week

Study Arms (4)

control group

Coronary heart disease population: after coronary angiography, Gensini score was used to evaluate the severity of coronary artery occlusion, and then compared with the population of type 2 diabetes complicated with coronary heart disease

Procedure: Coronary angiography

experimental group (course of disease <5 years)

Type 2 diabetes complicated with coronary heart disease (course of disease 5-10 years).Retrospective examination of patients' data, recording patients' laboratory tests and drug use, taking blood to measure orphanin, and evaluating the severity of coronary artery occlusion with Gensini score.

Procedure: Coronary angiography

experimental group(course of disease 5-10 years)

Type 2 diabetes complicated with coronary heart disease (course of disease 5-10 years).

Procedure: Coronary angiography

experimental group(course of disease10-20 years)

Type 2 diabetes complicated with coronary heart disease (course of disease 10 -20years).Finally, the data were obtained to evaluate the relationship between the course of diabetes and the severity of coronary heart disease, as well as the relationship between the course of diabetes and OFQ in patients' blood.

Procedure: Coronary angiography

Interventions

Coronary angiography was performed in patients with coronary heart disease complicated with type 2 diabetes mellitus

control groupexperimental group (course of disease <5 years)experimental group(course of disease 5-10 years)experimental group(course of disease10-20 years)

Eligibility Criteria

Age30 Years - 90 Years
Sexall
Healthy VolunteersNo
Age GroupsAdult (18-64), Older Adult (65+)
Sampling MethodNon-Probability Sample
Study Population

Type 2 diabetes complicated with coronary heart disease

You may qualify if:

  • The main discharge diagnosis is T2DM;;
  • Age \> 18 years old;
  • No acute complications of diabetes;
  • The previous diagnosis was coronary heart disease

You may not qualify if:

  • T1DM patients;
  • EGFR \< 60 ml/min/1.73 m or proteinuria (or both);
  • Patients with history of acute cardiovascular events;
  • Familial hypercholesterolemia or other hereditary lipid metabolism diseases;
  • anti-HIV patients;
  • Patients with serious mental health problems;
  • Patients receiving drugs that can lead to dyslipidemia, such as antipsychotics, corticosteroids, or immunosuppressants;
  • Patients with systemic inflammatory diseases, such as systemic lupus erythematosus; Pet-name ruby is quitting smoking and severe obesity (BMI\>40).

Contact the study team to confirm eligibility.

Sponsors & Collaborators

Study Sites (1)

Second of Shanxi Medical University

Taiyuan, Shanxi, 030001, China

Location

Biospecimen

Retention: SAMPLES WITH DNA

Serum orphanin FQ,Glycosylated hemoglobin

MeSH Terms

Conditions

Diabetes Mellitus, Type 2

Condition Hierarchy (Ancestors)

Diabetes MellitusGlucose Metabolism DisordersMetabolic DiseasesNutritional and Metabolic DiseasesEndocrine System Diseases

Study Officials

  • zheng guo, doctor

    Second Hospital of Shanxi Medical University

    PRINCIPAL INVESTIGATOR

Study Design

Study Type
observational
Observational Model
CASE CONTROL
Time Perspective
RETROSPECTIVE
Sponsor Type
OTHER
Responsible Party
PRINCIPAL INVESTIGATOR
PI Title
principal investigation

Study Record Dates

First Submitted

September 29, 2020

First Posted

October 1, 2020

Study Start

October 10, 2020

Primary Completion

June 1, 2021

Study Completion

September 30, 2021

Last Updated

April 20, 2022

Record last verified: 2022-04

Data Sharing

IPD Sharing
Will not share

All IPD that underlie results in a publication

Locations